Skin Cancer (Other than Melanoma)

New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma

2023-05-20

  • Study

    Open-label, multicenter, single-arm, phase 2 study
    Treatment naïve metastatic or recurrent locally advanced MCC
    Retifanlimab q28 (n=65)


  • Efficacy

    ORR: 52% [40.0%-65.0%]; cR:18%
    DOR6 mos: 76% [26 pts of 34]
    DOR12 mos: 62% [21 pts of 34]

  • Safety

    Any grade AEs: Fatigue, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia, and nausea.


    • https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334Orig1s000correctedlbl.pdf

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334Orig1s000correctedlbl.pdf

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Elvin Chalabiyev, MD on May 20, 2023